NICE Issues Technology Appraisal Guidance for Brigatinib
It is recommended in patients with ALK-positive advanced NSCLC who have already had crizotinib
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
EMA Starts Review on Screening Patients Before Treatment with Fluorouracil, Capecitabine, Tegafur and Flucytosine
EMA will assess available data in relation to existing screening methods to detect DPD deficiency
FDA Approves Atezolizumab for Extensive-Stage SCLC
Approval is based on results from the IMpower133 study
NICE Issues Technology Appraisal Guidance on Tisagenlecleucel for Treating Relapsed or Refractory DLBCL
It is recommended for use as an option for treatment of adults with diffuse large B-cell lymphoma after 2 or more systemic therapies
Cancer Neoantigens: Implications for Immune Response and Cancer Immunotherapy
Tumour specific splicing presents a large new class of splicing associated potential neoantigens
Persistent Long-term Fatigue Among Epithelial Ovarian Cancer Survivors
Findings from GINECO case-control study
FDA Approves Atezolizumab for PD-L1 Positive Unresectable Locally Advanced or Metastatic TNBC
Approval is based on results from the IMpassion130 trial
NICE Issues Technology Appraisal Guidance on Encorafenib with Binimetinib
They are recommended as an option for treatment of adults with unresectable or metastatic BRAF V600 mutation-positive melanoma
NICE Issues Technology Appraisal Guidance on Abemaciclib with an Aromatase Inhibitor
Recommendations concern previously untreated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer
Biosimilars have a fascinating story of development and understanding it is crucial for widespread adoption
Biosimilars have a fascinating story of development, says Rosa Giuliani, and understanding it is crucial for widespread adoption.
EMA Recommends Approval of Pazenir for the Treatment of Metastatic Breast Cancer and NSCLC
Pazenir is a generic of Abraxane which has been authorised in the EU since 2008
EMA Recommends Granting a Conditional Marketing Authorisation for Lorlatinib
It is intended for treatment of patients with ALK-positive advanced NSCLC previously treated with other ALK tyrosine kinase inhibitors